Lipemia retinalis in acquired immunodeficiency syndrome treated with protease inhibitors.
Eng
K T
KT
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Liu
E S
ES
Silverman
M S
MS
Berger
A R
AR
D000163:Acquired Immunodeficiency Syndrome / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D000328:Adult; D002784:Cholesterol / Q000097:blood; D020008:Delavirdine / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D017320:HIV Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis; D008297:Male; D012164:Retinal Diseases / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis; D012171:Retinal Vessels / Q000187:drug effects* / Q000473:pathology; D019438:Ritonavir / Q000009:adverse effects / Q000627:therapeutic use; D019258:Saquinavir / Q000009:adverse effects / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood; D019562:Viral Load; D016047:Zalcitabine / Q000009:adverse effects / Q000627:therapeutic use
D017320:HIV Protease Inhibitors; D014280:Triglycerides; D016047:Zalcitabine; D002784:Cholesterol; D020008:Delavirdine; D019258:Saquinavir; D019438:Ritonavir